Assets Held for Sale and Sale of Former Hungarian Subsidiary

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]

Assets Held for Sale and Sale of Former Hungarian Subsidiary

Assets Held for Sale and Sale of Former Hungarian Subsidiary

In the fourth quarter of 2013, we announced we would begin winding down Codexis’ CodeXyme^® cellulase enzyme program. We performed a detailed review of our excess research and development equipment and determined their estimated net sales price, less selling costs, was below their carrying value, reduced the value of held for sale assets to their estimated fair market value net of selling expenses and reclassified the adjusted carrying value to assets held for sale as of December 31, 2013.

In March 2014, we entered into an agreement with Intrexon Corporation to sell 100% of our equity interests in our Hungarian subsidiary, Codexis Laboratories Hungary Kft, as well as all assets of such subsidiary that were classified as held for sale. We received cash proceeds of $1.5 million from the sale. In connection with the sale, we reduced the carrying value of assets held for sale by $0.8 million and recognized a gain of $0.8 million, which was included in research and development expenses. As part of the purchase, the buyer obtained all of the Hungarian assets held for sale and assumed all employment and facility lease related contract obligations. There were no transaction related costs incurred other than legal fees, which were recorded in selling, general and administrative expenses.

Prior to the sale of our Hungarian subsidiary in March 2014, we transferred certain of the subsidiary's equipment to another of our European subsidiaries and incurred a reclaimable VAT liability of approximately $0.4 million. We paid this VAT amount in July 2014 and recorded a receivable, which is reflected in prepaid expenses and other current assets in our consolidated balance sheets at December 31, 2015. In 2016, we wrote off the receivable due to the uncertainty of collection of the reclaimable VAT.

In 2014, we expedited the disposition of assets held for sale in the United States by selling these assets through auction. As a result, we recognized a change in estimated fair value of $0.7 million in 2014, which is reflected in research and development expense. In addition, we revised our plan to sell certain U.S. research and development equipment. As part of the revised plan, certain equipment was put back to operational use. We also exchanged certain of the U.S. research and development equipment for more suitable and newer equipment that was classified as property and equipment. The combined transfer of U.S. research and development equipment from assets held for sale to property and equipment was $0.3 million. We recognized a net loss on the disposition and exchange of assets held for sale of less than $0.1 million in 2014.

As of December 31, 2016 and 2015, we had no assets classified as held for sale.